BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 20542421)

  • 1. Trastuzumab in gastric cancer.
    Okines AF; Cunningham D
    Eur J Cancer; 2010 Jul; 46(11):1949-59. PubMed ID: 20542421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.
    Norman G; Rice S; Spackman E; Stirk L; Danso-Appiah A; Suh D; Palmer S; Eastwood A
    Health Technol Assess; 2011 May; 15 Suppl 1():33-42. PubMed ID: 21609651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [HER2 and gastric cancer: a novel therapeutic target for trastuzumab].
    Bouché O; Penault-Llorca F
    Bull Cancer; 2010 Dec; 97(12):1429-40. PubMed ID: 21134821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport].
    Shen L; Xu JM; Feng FY; Jiao SC; Wang LW; Li J; Guan ZZ; Qin SK; Wang JJ; Yu SY; Wang YJ; Jin YN; Tao M; Zheng LZ; Pan LX
    Zhonghua Zhong Liu Za Zhi; 2013 Apr; 35(4):295-300. PubMed ID: 23985260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER2 testing in gastric cancer.
    Albarello L; Pecciarini L; Doglioni C
    Adv Anat Pathol; 2011 Jan; 18(1):53-9. PubMed ID: 21169738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How will human epidermal growth factor receptor 2-neu data impact clinical management of gastric cancer?
    Lorenzen S; Lordick F
    Curr Opin Oncol; 2011 Jul; 23(4):396-402. PubMed ID: 21505336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2 testing in gastric and esophageal adenocarcinoma: new diagnostic challenges arising from new therapeutic options.
    Koltz BR; Hicks DG; Whitney-Miller CL
    Biotech Histochem; 2012 Jan; 87(1):40-5. PubMed ID: 21745161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted HER2 treatment in advanced gastric cancer.
    Jørgensen JT
    Oncology; 2010; 78(1):26-33. PubMed ID: 20185938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
    Baselga J; Perez EA; Pienkowski T; Bell R
    Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [HER2 testing and targeted therapy in advanced gastric cancer].
    Höhler T; Rüschoff J; Ridwelski K; Moehler M
    Onkologie; 2010; 33 Suppl 4():26-30. PubMed ID: 20431310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target.
    De Vita F; Giuliani F; Silvestris N; Catalano G; Ciardiello F; Orditura M
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S11-5. PubMed ID: 21129604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trastuzumab: a new treatment option for HER2-positive metastatic gastric and gastroesophageal junction cancer.
    Lordick F
    Future Oncol; 2011 Feb; 7(2):187-99. PubMed ID: 21345138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer.
    Bang YJ
    J Clin Gastroenterol; 2012 Sep; 46(8):637-48. PubMed ID: 22751336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines.
    Gong SJ; Jin CJ; Rha SY; Chung HC
    Cancer Lett; 2004 Oct; 214(2):215-24. PubMed ID: 15363548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab for gastric cancer.
    Meza-Junco J; Au HJ; Sawyer MB
    Expert Opin Biol Ther; 2009 Dec; 9(12):1543-51. PubMed ID: 19916733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER-2 amplification is highly homogenous in gastric cancer.
    Marx AH; Tharun L; Muth J; Dancau AM; Simon R; Yekebas E; Kaifi JT; Mirlacher M; Brümmendorf TH; Bokemeyer C; Izbicki JR; Sauter G
    Hum Pathol; 2009 Jun; 40(6):769-77. PubMed ID: 19269014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era.
    Montemurro F; Redana S; Viale G; Sanna G; Donadio M; Valabrega G; del Curto B; Bottini A; Botti G; dei Tos AP; Jacomuzzi ME; Di Bonito M; Danese S; Clavarezza M; Kulka J; Di Palma S; Durando A; Sapino A; Aglietta M
    Clin Breast Cancer; 2008 Oct; 8(5):436-42. PubMed ID: 18952558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER-2-targeted therapy: lessons learned and future directions.
    Nahta R; Esteva FJ
    Clin Cancer Res; 2003 Nov; 9(14):5078-84. PubMed ID: 14613984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer.
    Okines AF; Cunningham D
    Therap Adv Gastroenterol; 2012 Sep; 5(5):301-18. PubMed ID: 22973416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A retrospective analysis of trastuzumab-based therapy in metastatic breast cancer patients at Masaryk Memorial Cancer Institute. Identification of predictive factors].
    Svoboda M; Grell P; Simícková M; Fabian P; Petráková K; Palácová M; Macková D; Trojanec R; Hajdúch M; Pavlík T; Nenutil R; Vyzula R
    Klin Onkol; 2008; 21(6):348-58. PubMed ID: 19382598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.